BRNS — Barinthus Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Barinthus Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.1 | 5.32 | -73.4 | -61.2 | -66.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 24.9 | -15.4 | 14 | 23.9 | 13.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.84 | -4.31 | 6.17 | 2.6 | -0.359 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -32.6 | -14.4 | -50.9 | -28.9 | -48 |
| Capital Expenditures | -1.15 | -6.14 | -5.41 | -0.892 | -0.037 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -11.8 | 0.388 | 0 | — | 0.453 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -12.9 | -5.75 | -5.41 | -0.892 | 0.416 |
| Financing Cash Flow Items | -5.27 | 0 | -0.163 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 223 | 0.325 | 1.87 | 2.16 | 0.002 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 171 | -19.7 | -52.3 | -29.7 | -40.5 |